Filtros de búsqueda

Lista de obras de Ryohei Katayama

3D culture system containing gellan gum restores oncogene dependence in ROS1 rearrangements non-small cell lung cancer

artículo científico publicado en 2018

A safety study of newly generated anti-podoplanin-neutralizing antibody in cynomolgus monkey (Macaca fascicularis)

artículo científico publicado en 2018

ALK Rearrangements Are Mutually Exclusive with Mutations in EGFR or KRAS: An Analysis of 1,683 Patients with Non–Small Cell Lung Cancer ⬇️

artículo científico publicado el 31 de mayo de 2013

AP-1-Dependent miR-21 Expression Contributes to Chemoresistance in Cancer Stem Cell-Like SP Cells ⬇️

artículo científico publicado el 1 de enero de 2010

APC Mutations as a Potential Biomarker for Sensitivity to Tankyrase Inhibitors in Colorectal Cancer.

artículo científico publicado en 2017

Acquired Resistance to Crizotinib from a Mutation in CD74 – ROS1

artículo científico publicado en 2013

Apollon ubiquitinates SMAC and caspase-9, and has an essential cytoprotection function

artículo científico publicado en 2004

Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer.

artículo científico publicado en 2017

Cabozantinib overcomes crizotinib resistance in ROS1 fusion-positive cancer

artículo científico publicado en 2015

Casein kinase 2-interacting protein-1, a novel Akt pleckstrin homology domain-interacting protein, down-regulates PI3K/Akt signaling and suppresses tumor growth in vivo.

artículo científico publicado en 2007

Cell differentiation inducers derived from thalidomide.

artículo científico publicado en 2005

Cell-permeable Carboxyl-terminal p27Kip1 Peptide Exhibits Anti-tumor Activity by Inhibiting Pim-1 Kinase

artículo científico publicado en 2011

Cellular FLIP inhibits beta-catenin ubiquitylation and enhances Wnt signaling.

scientific article published on October 2004

Complex N-glycosylated form of nicastrin is stabilized and selectively bound to presenilin fragments.

artículo científico publicado en 2002

Cytotoxic activity of tivantinib (ARQ 197) is not due solely to c-MET inhibition.

artículo científico publicado en 2013

Dofequidar fumarate sensitizes cancer stem-like side population cells to chemotherapeutic drugs by inhibiting ABCG2/BCRP-mediated drug export.

artículo científico publicado en 2009

Drug resistance in anaplastic lymphoma kinase-rearranged lung cancer

artículo científico publicado en 2018

Drug resistance mechanisms in Japanese anaplastic lymphoma kinase-positive non-small cell lung cancer and the clinical responses based on the resistant mechanisms

scientific article published on 08 February 2020

Epithelial-to-Mesenchymal Transition Is a Mechanism of ALK Inhibitor Resistance in Lung Cancer Independent of ALK Mutation Status

scientific article published on 08 February 2019

GSK3 inhibition circumvents and overcomes acquired lorlatinib resistance in ALK-rearranged non-small-cell lung cancer

artículo científico publicado en 2022

Gilteritinib overcomes lorlatinib resistance in ALK-rearranged cancer

artículo científico publicado en 2021

Identification of mutation accumulation as resistance mechanism emerging in first-line osimertinib treatment.

artículo científico publicado en 2018

Impairment of the ubiquitin-proteasome system by cellular FLIP.

artículo científico publicado en 2007

Mechanisms of Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancers ⬇️

artículo científico publicado el 25 de enero de 2012

Mechanisms of Resistance to NTRK Inhibitors and Therapeutic Strategies in NTRK1-Rearranged Cancers

artículo científico publicado en 2017

Modulation of Wnt signaling by the nuclear localization of cellular FLIP-L.

artículo científico publicado en 2010

Monitoring epidermal growth factor receptor C797S mutation in Japanese non-small cell lung cancer patients with serial cell-free DNA evaluation using digital droplet PCR

artículo científico publicado en 2021

Overcoming resistance by ALK compound mutation (I1171S + G1269A) after sequential treatment of multiple ALK inhibitors in non-small cell lung cancer

scientific article published on 13 January 2020

P-glycoprotein Mediates Ceritinib Resistance in Anaplastic Lymphoma Kinase-rearranged Non-small Cell Lung Cancer

artículo científico publicado en 2015

PF-06463922, an ALK/ROS1 Inhibitor, Overcomes Resistance to First and Second Generation ALK Inhibitors in Preclinical Models

artículo científico publicado en 2015

Patient-derived models of acquired resistance can identify effective drug combinations for cancer.

artículo científico publicado en 2014

Pim kinases promote cell cycle progression by phosphorylating and down-regulating p27Kip1 at the transcriptional and posttranscriptional levels

artículo científico publicado en 2008

Prediction of ALK mutations mediating ALK-TKIs resistance and drug re-purposing to overcome the resistance

scientific article published on 17 January 2019

RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer

artículo científico publicado en 2015

Recurrent 8q24 rearrangement in blastic plasmacytoid dendritic cell neoplasm: association with immunoblastoid cytomorphology, MYC expression, and drug response

scientific article published on 23 May 2018

Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.

artículo científico publicado en 2016

Secreted PD-L1 variants mediate resistance to PD-L1 blockade therapy in non-small cell lung cancer

scientific article published on 14 March 2019

TKI-addicted ROS1-rearranged cells are destined to survival or death by the intensity of ROS1 kinase activity.

artículo científico publicado en 2017

TUSC4/NPRL2, a novel PDK1-interacting protein, inhibits PDK1 tyrosine phosphorylation and its downstream signaling

artículo científico publicado en 2008

The ALK Inhibitor Ceritinib Overcomes Crizotinib Resistance in Non-Small Cell Lung Cancer

artículo científico publicado en 2014

The new-generation selective ROS1/NTRK inhibitor DS-6051b overcomes crizotinib resistant ROS1-G2032R mutation in preclinical models

artículo científico publicado en 2019

Therapeutic strategies and mechanisms of drug resistance in anaplastic lymphoma kinase (ALK)-rearranged lung cancer.

artículo científico publicado en 2017

Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK.

artículo científico publicado en 2011

Therapeutic targeting of anaplastic lymphoma kinase in lung cancer: a paradigm for precision cancer medicine.

artículo científico

Tivantinib (ARQ 197) exhibits antitumor activity by directly interacting with tubulin and overcomes ABC transporter-mediated drug resistance

artículo científico publicado en 2014

Transforming growth factor-β decreases the cancer-initiating cell population within diffuse-type gastric carcinoma cells.

artículo científico publicado en 2010

Two novel ALK mutations mediate acquired resistance to the next-generation ALK inhibitor alectinib

artículo científico publicado en 2014

US phase 1 first-in-human study of taletrectinib (DS-6051b/AB-106), a ROS1/TRK inhibitor, in patients with advanced solid tumors

artículo científico publicado en 2020

Dominio Público Uruguay está sostenido por:

Acerca de Dominio Público Uruguay

Ayuda